Evidence map›Paper›PMID 34816397›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2022

Mammalian Cell Culture as a Platform for Veterinary Vaccines.

Thailín Lao González, Ileanet Ávalos Olivera, Alina Rodríguez-Mallon

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Thailín Lao GonzálezAnimal Biotechnology Department, Center for Genetic Engineering and Biotechnology, Havana, Cuba.
Ileanet Ávalos OliveraAnimal Biotechnology Department, Center for Genetic Engineering and Biotechnology, Havana, Cuba.
Alina Rodríguez-MallonAnimal Biotechnology Department, Center for Genetic Engineering and Biotechnology, Havana, Cuba. alina.rodriguez@cigb.edu.cu.
Centro de Ingeniería Genética y Biotecnología · CU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

For more than three decades, mammalian cells have been the host par excellence for the recombinant protein production for therapeutic purposes in humans. Due to the high cost of media and other supplies used for cell growth, initially this expression platform was only used for the production of proteins of pharmaceutical importance including antibodies. However, large biotechnological companies that used this platform continued research to improve its technical and economic feasibility. The main qualitative improvement was obtained when individual cells could be cultured in a liquid medium similar to bacteria and yeast cultures. Another important innovation for growing cells in suspension was the improvement in chemically defined media that does not contain macromolecules; they were cheaper to culture as any other microbial media. These scientific milestones have reduced the cost of mammalian cell culture and their use in obtaining proteins for veterinary use. The ease of working with mammalian cell culture has permitted the use of this expression platform to produce active pharmaceutic ingredients for veterinary vaccines. In this chapter, the protocol to obtain recombinant mammalian cell lines will be described.

Indexed as

Cell Culture TechniquesVaccinesAnimalsBiotechnologyCell LineCulture MediaHumansMammalsRecombinant ProteinsCulture MediaRecombinant ProteinsVaccinesCell cultureMammalian cellsProtein expressionSuspension cell cultureVeterinary vaccines

Identifiers

PMID34816397
OpenAlexW3216484987

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.